Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

1
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
1
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

2
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
2
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

1
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous...
1

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

Neuro-oncology advances·2022
Same author

"You can observe a lot by just watching" (Yogi Berra).

Neuro-oncology·2021
Same author

Leptomeningeal metastases: how best to assess response.

Neuro-oncology·2020
Same author

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Neuro-oncology·2018
Same author

Leptomeningeal metastasis.

Handbook of clinical neurology·2018
Same author

Immunochemotherapy, the New Standard of Care for Primary CNS Lymphoma: However, Which One?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2017

Related Experiment Video

Updated: Apr 17, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

Neoplastic myelopathies.

Marc C Chamberlain

    Continuum (Minneapolis, Minn.)
    |February 5, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Cancer frequently affects the spinal cord, causing dysfunction through direct or indirect mechanisms. Early diagnosis and palliative care are crucial for preserving neurologic function and quality of life in patients with neoplastic myelopathies.

    More Related Videos

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
    08:57

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

    Published on: May 17, 2024

    2.8K
    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
    06:39

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

    Published on: October 3, 2018

    10.3K

    Related Experiment Videos

    Last Updated: Apr 17, 2026

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
    09:33

    Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

    Published on: August 25, 2023

    1.9K
    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
    08:57

    Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

    Published on: May 17, 2024

    2.8K
    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
    06:39

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

    Published on: October 3, 2018

    10.3K

    Area of Science:

    • Neurology
    • Oncology
    • Spinal Cord Medicine

    Background:

    • Spinal cord involvement occurs in 5-10% of cancer patients.
    • Cancer can lead to spinal cord dysfunction via direct or indirect pathways.

    Purpose of the Study:

    • To review neoplastic disorders causing spinal cord dysfunction.
    • To highlight the importance of clinical suspicion for diagnosis and management.

    Main Methods:

    • Review of direct and indirect mechanisms of spinal cord involvement.
    • Classification of direct involvement by anatomic compartment: parenchymal, subarachnoid, and epidural.

    Main Results:

    • Direct mechanisms include intramedullary metastases, primary tumors, leptomeningeal metastases, and epidural compression.
    • Indirect mechanisms involve neurotoxicity from cancer treatment (radiation, chemotherapy) and paraneoplastic disorders.
    • Neoplastic myelopathies are not uncommon and require high clinical suspicion.

    Conclusions:

    • Prompt diagnosis of neoplastic myelopathies is essential in cancer patients with spinal cord symptoms.
    • Treatment is primarily palliative, aiming to preserve neurologic function and improve quality of life.